The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. METHODS: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. RESULTS: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22%, P=0.01). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). CONCLUSIONS: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in a prospective RCT, the addition of DFX to patients with proven or probable mucormycosis treated with antifungal liposomal amphotericin B increased the mortality (Spellberg et al., 2011).”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a recent clinical trial in patients after allogenic bone marrow transplantation who received the iron chelator desferrasirox in an attempt to improve the control of mucormycosis, a devastating invasive fungal infection in severely immuno-compromised patients, failed to show a clinical benefit (Spellberg et al., 2012).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Spellberg et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
In the citing paper
“However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590004 · Cited by 826
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Self-citationIncreasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
Self-citationThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Self-citation
Cited by
Items 201–300 of 311
Evolution of antifungals for invasive mold infections in immunocompromised hosts, then and now
Weiss, Z., Little, J. S., & Hammond, S. P. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2207821 · Cited by 6
Tashiro, M., Namie, H., Ito, Y., Takazono, T., Kakeya, H., Miyazaki, Y., Mukae, H., Mikamo, H., Tomoo, F., Shibuya, K., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad480 · Cited by 6
“…the 4-week survival rate of mucormycosis patients treated with high-dose (10 mg/kg/d) liposomal amphotericin B was 79% [25], whereas in another prospective study, the DEFEAT study by Spellberg et al., the 4-week survival rate of mucormycosis patients treated with the standard dose was 70% [26].”
Elgarten, C. W., Levy, E. M., Mattei, P., Fisher, B. T., Olson, T. S., & Freedman, J. L. (2018) · Pediatric Transplantation · doi:10.1111/petr.13270 · Cited by 6
Invasive Mold Infections in Children: Navigating Troubled Waters with a Broken Compass
Arrieta, A. C., Lee, A., & Tran, M. T. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00819-9 · Cited by 6
“In a small, randomized study, patients were allocated to receive liposomal amphotericin B with (11 patients) or without (9 patients) deferasirox; the former had the higher mortality at 30 and 90 days [77].”
BackgroundMaffini, F. A., Cocorocchio, E., Pruneri, G., Bonomo, G., Peccatori, F. A., Chiapparini, L., Vincenzo, S. D., Martinelli, G., & Viale, G. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2013.382 · Cited by 6
“Several other agents were investigated, like deferasirox, an Iron chelant agent that has an antifungal effect, synergistic with liposomial amphotericin B [24] or immunosuppressive agents like tacrolimus that could synergistically act with posaconazole or caspofungin [25].”
BackgroundThe VITAL study: case control studies are hypothesis-generating – Authors' reply
Cornely, O. A., Maher, R., Marty, F. M., Lee, M., Vehreschild, J. J., & Vehreschild, M. J. G. T. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30192-x · Cited by 6
[Successful treatment of rhino-orbital-cerebral mucormycosis in a kidney transplant patient].
Nieto‐Ríos, J. F., Moreno-Coral, L. F., Zapata–Cárdenas, A., Ocampo-Kohn, C., Aristizábal-Alzate, A., Serna-Higuita, L. M., Ramírez‐Sánchez, I. C., & Zuluaga-Valencia, G. A. (2014) · PubMed · doi:10.3265/nefrologia.pre2013.nov.12084 · Cited by 5
Tanwar, M., Singh, A., Singh, T. P., Sharma, S., & Sharma, P. K. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00082 · Cited by 5
The genome sequence of four isolates from the family Lichtheimiaceae
Chibucos, M. C., Etienne, K. A., Orvis, J., Lee, H.-K., Daugherty, S. C., Lockhart, S. R., Ibrahim, A. S., & Bruno, V. M. (2015) · Pathogens and Disease · doi:10.1093/femspd/ftv024 · Cited by 5
“Lichtheimia corymbifera CDC-B2541 was isolated as a plate contaminant in 1977 in Wisconsin, USA, while isolate 008-049 was isolated from a human in a 2008 DeferasiroxAmBisome Therapy for Mucormycosis (DEFEAT) study (Spellberg et al. 2012).”
BackgroundSelf-citationRenal mucormycosis complicating extracorporeal membrane oxygenation
Charles, P., Kahn, J., Ackermann, F., Honderlick, P., & Lortholary, O. (2013) · Medical Mycology · doi:10.3109/13693786.2012.686069 · Cited by 5
Treatment Options for Mucormycosis
Miceli, M. H., & Kauffman, C. A. (2015) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-015-0050-8 · Cited by 5
Current Antifungal Agents for Treatment of Central Nervous System Infections
Coulter, K. S., & Bariola, J. R. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0186-x · Cited by 5
Treatment of mucormycosis with liposomal Amphotericin B, posaconazole and deferasirox: A case report
Sıpahı, O. R., Önal, U., Tasbakan, M. I., Yamazhan, T., Arda, B., Pullukçu, H., & Ulusoy, S. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.03.1009 · Cited by 5
“, compared LAMB + deferasirox with LAMB+placebo in a small randomized controlled trial [7].”
MethodCombination Therapy for the Treatment of Mucormycosis: Examining the Evidence
Huang, A. M., Nagel, J. L., Crass, R. L., & Nguyen, C. T. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0222-5 · Cited by 5
Saullo, J. H., & Alexander, B. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00038-5 · Cited by 5
García‐Vidal, C., Vázquez, L., & Jarque, I. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.03.001 · Cited by 5
Mucormycosis (and entomophthoramycosis)
Davies, S. F. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139855952.197 · Cited by 5
Mucormycosis—Emerging Fungal Threats
Troiano, G., & Nante, N. (2022) · Encyclopedia · doi:10.3390/encyclopedia2010016 · Cited by 5
“further studies, it is better to use caution when administering deferasirox for patients with mucormycosis, even in a salvage setting [50].”
BackgroundTreatment of pulmonary mucormycosis: current concepts
Muthu, V., Sehgal, I. S., & Agarwal, R. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2622695 · Cited by 5
“Despite evidence from a few case reports and case series, a double-blind RCT of adjunctive deferasirox combined with LAMB in 20 mucormycosis patients failed to show better outcomes than LAMB alone [102,103].”
An extensive review on antifungal approaches in the treatment of mucormycosis
Chaudhari, H. S., Palkar, O. S., Mishra, K. A., & Sethi, K. K. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23417 · Cited by 4
Ni, T., Chi, X., Wu, H., Xie, F., Bao, J., Wang, J., Ji, Z., Li, L., Wang, X., Yan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116026 · Cited by 4
Chakrabarti, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_19 · Cited by 4
Pulmonary Mucormycosis in a Patient With Uncontrolled Diabetes.
Lipatov, K., Patel, C. D., Lat, T. I., Shakespeare, A., Wang, B., & Prakash, G. (2018) · Europe PMC (PubMed Central) · Cited by 4
A closer look at pathogenesis of cerebral mucormycosis in diabetic condition: A mini review
Khoshbayan, A., Didehdar, M., Chegini, Z., Taheri, F., & Shariati, A. (2021) · Journal of Basic Microbiology · doi:10.1002/jobm.202000692 · Cited by 5
Management of Acute Invasive Fungal Sinusitis
Swain, S. K. (2022) · Mustansiriya Medical Journal · doi:10.4103/mj.mj_42_22 · Cited by 4
Sirignano, S., Blake, P. W., Turrentine, J. E., & Dominguez, A. R. (2014) · Dermatology Online Journal · doi:10.5070/d3206022864 · Cited by 4
Xipell, M., Losno, R. A., García‐Vidal, C., Rovira, M., Alejo-Cancho, I., de la Bellacasa, J. P., López, M. R., Cardozo, C., Bodro, M., Mensa, J., et al. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.04.002 · Cited by 4
Infections in Hematopoietic Stem Cell Transplant Recipients in India – Think Global, Act Local
Prayag, P. S., & Chandrasekar, P. H. (2024) · Journal of Clinical Infectious Disease Society · doi:10.4103/cids.cids_48_24 · Cited by 3
Tóth, Z., Farkas, B., Majoros, L., Jakab, Á., Borman, A. M., Varga, I., Tóth, P., & Kovács, R. (2025) · Medical Mycology · doi:10.1093/mmy/myaf116 · Cited by 3
“49 , 50 An additional potential limitation in translating these findings to in vivo systems is that alternative iron acquisition mechanisms may compensate for the effects of deferiprone.”
Diagnostic et traitement des mucormycoses en 2014
Rammaert, B., & Lortholary, O. (2014) · Réanimation · doi:10.1007/s13546-014-0864-2 · Cited by 3
Farkas, E., Szabó, O., Gyémánt, G., Szaniszló, S., Szabó, Z., & Pócsi, I. (2018) · Transition Metal Chemistry · doi:10.1007/s11243-018-0225-5 · Cited by 4
Post COVID-19: What is role of iron and iron chelating agents?
Maurya, R. P. (2021) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.2021.052 · Cited by 6
A Systematic Review on Mucormycosis in Corona Patients and its Treatment in India
Ahmad, S. R. (2021) · JOURNAL OF COMMUNICABLE DISEASES · doi:10.24321/0019.5138.202163 · Cited by 3
Marketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid Overview.
Soltani, H., & Pardakhty, A. (2016) · PubMed Central · Cited by 3
Salvage Therapy for the Treatment of Mucormycosis
Patel, A. A., Bork, J. T., & Riedel, D. J. (2021) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-021-00250-z · Cited by 4
The VITAL study: case control studies are hypothesis-generating
Spellberg, B. J., & Brass, E. P. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30154-2 · Cited by 3
Self-citationSharma, M., & Chakrabarti, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00234-2 · Cited by 4
An Update on Fungal Orbital Infections
Chiou, C. A., & Yoon, M. K. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000407 · Cited by 3
Renal Allograft Mucormycosis: An Unusual Case Report
Mahapatra, H. S., Chaudhary, P., Muthukumar, B., Gupta, V., & Singh, B. S. (2023) · Indian journal of clinical medicine · doi:10.1177/26339447221149517 · Cited by 2
Lemhamdi, O., Willems, É., Baron, F., Prijck, B. D., Caers, J., Bouquegneau, A., Guiot, J., Cousin, F., Jadoul, A., Rogister, F., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1715663 · Cited by 2
Iron in respiratory immunity and infection
Martinelli, A. W., Jordan, R., Wugk, S., Nathan, J. A., & Cloonan, S. M. (2026) · QJM · doi:10.1093/qjmed/hcag090 · Cited by 2
Tsoulas, C., Tragiannidis, A., & Groll, A. H. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0166-6 · Cited by 2
Invasive Fungal Sinusitis in Immunocompromised Hosts
Chao, A. W., & Kontoyiannis, D. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-74835-1_15 · Cited by 3
Self-citationManagement of Mucorales Infections in Transplant Patients
Chen, S. C. ‐., & Slavin, M. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_45 · Cited by 2
Management of Mucorales Infections in Transplant Patients
Chen, S. C. ‐., & Slavin, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-01751-4_45-1 · Cited by 2
The ‘black fungus’ Co-Infection in COVID-19 Patients : A Review
Hadiyanto, J. N., Wilda, F., Cahyadi, A., & Adisuhanto, M. (2021) · Indonesian Journal of Tropical and Infectious Disease · doi:10.20473/ijtid.v9i2.27450 · Cited by 2
Mucormycosis in COVID-19 patients: A cross-sectional study at IGIMS, Patna
Yasmeen, T., Prasad, N., Kumar, V., Sinha, S., Kumar, S., & Sanjay Kumar, S. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_358_23 · Cited by 2
Role of Deferasirox as an Adjuvant to Parenteral Antifungal Therapy in Invasive Fungal Sinusitis
Chavan, S. S., MEHERE, Y., KHOND, A., & RADHAKRISHNAN, R. (2021) · Egyptian Journal of Ear Nose Throat and Allied Sciences · doi:10.21608/ejentas.2021.70482.1349 · Cited by 1
“Second, efficacy of deferasirox was most apparent in mice with DKA, which have increased free iron levels, and efficacy was substantially less apparent in neutropenic mice[9].”
BackgroundTreatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report
Önal, U. (2015) · Journal of Microbiology and Infectious Diseases · doi:10.5799/jmid.328767 · Cited by 1
Isolated Tracheal Mucormycosis - A Rare Entity
Ramanan, R., Chandran, D., Nahan, R., & Ashok, H. (2023) · Acta Scientific Otolaryngology · doi:10.31080/asol.2023.05.0585 · Cited by 1
Vágó, B., Bauer, K., Varghese, N., Kiss-Vetráb, S., Kocsubé́, S., Varga, M., Szekeres, A., Vágvölgyi, C., Papp, T., & Nagy, G. (2025) · Microbial Cell · doi:10.15698/mic2025.08.856 · Cited by 1
“This treatment is one of the most significant risk factors for mucormycosis [28].”
Gu, Y., Ibrahim, B. A., Gebremariam, T., Alkhazraji, S., Aerts, R., Vanbiervliet, Y., Lagrou, K., Maertens, J. A., Prattes, J., Egger, M., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.01790-25 · Cited by 1
“…University of Texas Health Sciences Center at San Antonio), L. corymbifera 008-0490 (obtained from a patient that was enrolled in the DEFEAT Mucor clinical trial) (33), C. bertholletiae 182 (a gift from Dr. Thomas Walsh), and Rhizomucor (obtained from a patient at the Harbor-UCLA Medical Center).”
Self-citationHu, L., Luan, J., Liu, X., Zhang, Z., Tong, Z., Qu, Y., Jiang, Z., & Lin, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s595236 · Cited by 1
“14,15 In mammals, iron sequestration is primarily mediated by transferrin-family iron-binding proteins.”
Violaceous Necrotic Plaques on the Leg of an Immunosuppressed Patient
Xu, S., Nambudiri, V. E., Tahan, S. R., & Seo, S. J. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5322 · Cited by 1
Lyons, J. L. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0376-7 · Cited by 1
Molina, J. R., Rojas, R., Serrano, J., & Gómez, P. (2012) · Journal of Hematological Malignancies · doi:10.5430/jhm.v2n4p1 · Cited by 1
“with mucormycosis treated with deferasirox and L-AmB had a higher mortality rate at 90 days and concluded that these data do not support a role for initial adjunctive deferasirox therapy for mucormycosis ([93]).”
ResultA 29‐Year‐Old Man with Hospital‐Acquired Cavitary Pneumonia
Mehmood, M., Halloush, R. A., & Khasawneh, F. A. (2014) · Canadian Respiratory Journal · doi:10.1155/2014/614148 · Cited by 1
Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients
Perissinotti, A. J., & Marini, B. L. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0303-8 · Cited by 1
Sinkó, J. (2018) · Hematológia–Transzfuziológia · doi:10.1556/2068.2018.51.3.4 · Cited by 1
Kamath, V., Mathivanan, M., Vinay, R. B., & Nivea, B. (2021) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_74_21 · Cited by 1
Mucormycosis with Ca Breast Cancer
Dethe, S. R., Telang, P., & Thorat, R. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i60b34890 · Cited by 1
“Attending the guide group makes her feel a feel of community and is aware of that she isn't always by myself in this struggle [9].”
BackgroundAntifungal Therapy in Rhino-Orbito-Cerebral Mucormycosis (ROCM)
Soman, R. N., & Rege, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9729-6_15 · Cited by 1
Nemade, S. V., & Shinde, K. J. (2021) · Springer eBooks · doi:10.1007/978-981-16-4047-6_13 · Cited by 1
COVID-19 pneumonitis and mucormycosis in a COVID-19 vaccinated individual
Balwani, M. R., Tolani, P. R., Pasari, A. S., & Bhawane, A. R. (2022) · Journal of The Nephrology Society · doi:10.4103/jtns.jtns_16_22 · Cited by 1
Swain, S. K., & Jena, P. P. (2022) · Journal of the Scientific Society · doi:10.4103/jss.jss_56_21 · Cited by 1
Epidemiology and Management of Mucormycosis in India – Pre- and Post-COVID-19
Sethuraman, N. (2021) · Journal of Association of Pulmonologist of Tamil Nadu · doi:10.4103/japt.japt_42_21 · Cited by 1
The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research
Lewis, R. E. (2024) · Journal of Fungi · doi:10.3390/jof10060382 · Cited by 1
“Dim-itrios helped design and complete the only placebo-controlled, double-blind randomized controlled trial performed for mucormycosis that evaluated deferasirox–liposomal amphotericin B therapy for mucormycosis [76].”
BackgroundManagement of Pulmonary Mucormycosis: A Systematic Review
Fadelelmoula, T. E. Y., Ayyalil, N., & Doreswamy, N. (2024) · F1000Research · doi:10.12688/f1000research.151564.1 · Cited by 2
Mucormycosis Presenting as Orbital Cellulitis; A Case Report
Stuart, A. J. (2015) · Advances in Ophthalmology & Visual System · doi:10.15406/aovs.2015.03.00078 · Cited by 1
“However, in a human model desafirox was associated with higher incidence of mortality than placebo [15].”
BackgroundNakazato, G., Fávaro, W. J., & Durán, N. (2021) · doi:10.21467/preprints.330 · Cited by 1
Maschmeyer, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_10 · Cited by 1
Maziarz, E. K., & Perfect, J. R. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0029 · Cited by 1
Self-citationOptimisation du traitement préventif et curatif de la mucormycose pulmonaire
Brunet, K. (2020) · theses.fr (ABES) · doi:10.70675/1367c1e7zd412z4f2ez9be3zb15a2d64bb30 · Cited by 2
14 Therapeutic Strategies in Fungal Infections
Vehreschild, M. J. G. T., Wahlers, K., & Cornely, O. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-39432-4_14
40 years of medical mycology at JAC
Ostrosky-Zeichner, L. L. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw420
Infectious Diseases: Deep Fungal Infections
Motaparthi, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-43630-2_17
Wu, Y. L., Hu, J., Yang, G., Jin, B. Y., & Wang, Z. R. (1983) · PubMed
Lai, Y. (2016) · The Sydney eScholarship Repository (The University of Sydney)
Cerebellar Mucormycosis in a Young Man: A Case Report
Mashhadinezhad, H., & Mehrizi, M. A. A. (2017) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid.62962
“However, the safety of this combination therapy is still controversial and administration of deferasirox is not recommended in mucormycosis patients because a higher mortality with this drug was observed in trials (13, 14).”
BackgroundAntifungal Consideration for Transplant Recipients
Dubrovskaya, Y., Merl, M. Y., Perlin, D. S., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_52
Investigating the impact of polymicrobial interactions on fungal pathogenicity
Kousser, C. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
Mucormycosis, fusariosis, scedosporiasis, and other invasive mold diseases
Wattier, R. L., & Steinbach, W. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64198-2.00034-8 · Cited by 1
Coronavirus disease 2019-associated mucormycosis – A syndemic
Priyadarshi, M., Praveen, T., Mittal, A., Singh, G., Xess, I., & Wig, N. (2021) · The Journal of Clinical and Scientific Research · doi:10.4103/jcsr.jcsr_51_21
Haddad, N., Bechwati, M., Ayoub, H., Zeenny, R. M., & Kanj, S. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00140-7 · Cited by 1
Faculty Opinions recommendation of Molecular mechanisms of mucormycosis-The bitter and the sweet.
Lortholary, O. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727876937.793550314
Prevention and Treatment of COVID-19-Associated Mucormycosis
Grafmiller, K. T., & Lee, J. T. (2023) · Current Treatment Options in Allergy · doi:10.1007/s40521-023-00339-4
Mace, M. A. M., da Costa, B. S., Fuentefria, R. D. N., & Fuentefría, A. M. (2023) · Clinical & Biomedical Research · doi:10.22491/2357-9730.122904
The Black Fungal: Mucormycosis
Kumbhar, R. P., Kothavale, S. D., Vharamble, J. S., & Yadav, P. P. (2023) · Research Journal of Science and Technology · doi:10.52711/2349-2988.2023.00024
Chaurpagar, R. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23627011311
Mucormycosis: Current Perspectives on Treatment, Diagnosis, and Advancements
Biswas, T., Sharma, V., & Mittal, R. K. (2024) · Coronaviruses · doi:10.2174/0126667975333545241011060632
Invasive Fungal Sinusitis in Immunocompromised Hosts
Sharma, D., Chao, A. W., & Kontoyiannis, D. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-68449-4_16
Self-citationNon-Aspergillus Pulmonary Mold Infections
Muthu, V., & Chakrabarti, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_25
Parveen, S., Agrawal, R., Kshirsagar, M. M., Bhambhani, D., Bhambhani, G., Bharti, C., Sharma, N., Patadiya, H. H., & Mehta, M. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_21_25
Mucormycosis and Entomophthoramycosis
Wattier, R. L., & Steinbach, W. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00223-5
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
Eichenberger, E. M., Mendoza, M. A., & Baddley, J. W. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100382
“15,34,35 To optimize culture yield, it is recommended to slice tissue rather than grind specimens.”
Pulmonary mucormycosis complicated with transplant renal dysfunction: A case report
Qian, X., Hong, Z., Wang, R., & Ping, J. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102310
“[5].”
Combination therapy in invasive mucormycosis
Shah, M. D., Gibbons, E. A., & Gutierrez, G. C. (2025) · American Journal of Pharmacotherapy and Pharmaceutical Sciences · doi:10.25259/ajpps_2025_014
Infeções por zigomicetos da ordem mucorales : patogénese, epidemiologia e terapêutica
Gina, A. G. S. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Inclán, M., Clares, M. P., Álvarez-Duarte, E., Fernández‐Silva, F., Salas, V., Guarro, J., Chicote, J. U., Verdejo, B., Delgado‐Pinar, E., García‐España, E., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c09700
Metadata
- Authors
- Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P.
- Affiliations
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Duke Medical Center (US)
- University of Washington (US)
- Corresponding author
- Spellberg, Brad
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 67
- Issue
- 3
- Pages
- 715-722
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3383100
- OpenAlex
- W2116858171
- Cited by
- 308
- References
- 32
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 9 · 2023: 22 · 2022: 24 · 2021: 30 · 2020: 16 · 2019: 20 · 2018: 22 · 2017: 16 · 2016: 22 · 2015: 17 · 2014: 33 · 2013: 25 · 2012: 19
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Gilead Sciences
- Astellas Pharma
- National Institutes of Health (UL1TR000124)
- National Institute of Allergy and Infectious Diseases (R01AI081719, R01AI063503)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
- Keywords
- mucormycosis, deferasirox, liposomal amphotericin B, iron chelation, adjunctive therapy, mortality, treatment safety
- MeSH terms
- Deferasirox, Adult, Aged, Amphotericin B, Animals, Antifungal Agents, Benzoates, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Iron Chelating Agents, Male, Middle Aged, Mucormycosis, Placebos, Triazoles, Survival Analysis, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.